LT3466949T - Triciklinis junginys kaip priešvėžinis agentas - Google Patents

Triciklinis junginys kaip priešvėžinis agentas

Info

Publication number
LT3466949T
LT3466949T LTEP18192207.1T LT18192207T LT3466949T LT 3466949 T LT3466949 T LT 3466949T LT 18192207 T LT18192207 T LT 18192207T LT 3466949 T LT3466949 T LT 3466949T
Authority
LT
Lithuania
Prior art keywords
agent
tricycle compound
tricycle
compound
Prior art date
Application number
LTEP18192207.1T
Other languages
English (en)
Inventor
Derek J. Norris
George V. Delucca
Ashvinikumar V. Gavai
Claude A. Quesnelle
Patrice Gill
Daniel O`MALLEY
Wayne Vaccaro
Francis Y. Lee
Mikkel V. DEBENEDETTO
Andrew P. Degnan
Haiquan Fang
Matthew D. Hill
Hong Huang
William D. Schmitz
Starrett, Jr
Wen-Ching Han
John S. Tokarski
Sunil Kumar MANDAL
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3466949T publication Critical patent/LT3466949T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
LTEP18192207.1T 2013-12-24 2014-12-23 Triciklinis junginys kaip priešvėžinis agentas LT3466949T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24

Publications (1)

Publication Number Publication Date
LT3466949T true LT3466949T (lt) 2021-03-25

Family

ID=52293305

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18192207.1T LT3466949T (lt) 2013-12-24 2014-12-23 Triciklinis junginys kaip priešvėžinis agentas
LTEP14824743.0T LT3087071T (lt) 2013-12-24 2014-12-23 Tricikliniai junginiai kaip priešvėžiniai agentai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP14824743.0T LT3087071T (lt) 2013-12-24 2014-12-23 Tricikliniai junginiai kaip priešvėžiniai agentai

Country Status (34)

Country Link
US (1) US20160318928A1 (lt)
EP (2) EP3466949B1 (lt)
JP (2) JP6466456B2 (lt)
KR (1) KR102457145B1 (lt)
CN (2) CN108558871B (lt)
AR (2) AR099379A1 (lt)
AU (1) AU2014369982B2 (lt)
BR (1) BR112016013744B1 (lt)
CA (1) CA2934953C (lt)
CL (1) CL2016001629A1 (lt)
CY (2) CY1121076T1 (lt)
DK (2) DK3087071T3 (lt)
EA (2) EA201990240A1 (lt)
ES (2) ES2857848T3 (lt)
HR (2) HRP20181849T1 (lt)
HU (2) HUE041719T2 (lt)
IL (1) IL246359B (lt)
LT (2) LT3466949T (lt)
MA (1) MA39211B1 (lt)
MX (1) MX369491B (lt)
MY (1) MY176489A (lt)
NZ (1) NZ722326A (lt)
PE (1) PE20160844A1 (lt)
PH (1) PH12016500953A1 (lt)
PL (2) PL3087071T3 (lt)
PT (2) PT3087071T (lt)
RS (2) RS61479B1 (lt)
SG (1) SG11201605097SA (lt)
SI (2) SI3466949T1 (lt)
SM (2) SMT202100165T1 (lt)
TN (1) TN2016000238A1 (lt)
TW (2) TWI726544B (lt)
UY (1) UY35916A (lt)
WO (1) WO2015100282A1 (lt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
ES2857848T3 (es) * 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
US9580430B2 (en) * 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
BR112018006689A2 (pt) * 2015-10-02 2018-10-09 Dana Farber Cancer Inst Inc terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle
WO2017124934A1 (zh) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的含膦咔啉衍生物
KR102238012B1 (ko) * 2016-01-20 2021-04-09 닝보 웬다 파르마 테크놀로지 엘티디 브로모도메인 억제제인 카르볼린 유도체
CN108770356A (zh) * 2016-02-05 2018-11-06 正大天晴药业集团股份有限公司 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
WO2017151613A1 (en) * 2016-03-01 2017-09-08 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA3045855A1 (en) 2016-11-10 2018-05-17 Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
CN109824693B (zh) * 2017-04-18 2020-12-08 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
CN111356695B (zh) * 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
SG11202012819YA (en) 2018-06-25 2021-01-28 Jacobio Pharmaceuticals Co Ltd Tricyclic compounds
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020200284A1 (zh) * 2019-04-04 2020-10-08 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
TW202126638A (zh) 2019-09-30 2021-07-16 日商協和麒麟股份有限公司 Bet分解劑
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CA3206066A1 (en) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents
MX2023009858A (es) * 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
US12016847B2 (en) * 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
EP4334286A4 (en) * 2021-05-06 2025-03-19 Raziel Therapeutics Ltd. CRYSTALLINE CARBAZOLE DERIVATIVE
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8815840B2 (en) * 2008-12-19 2014-08-26 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
UY33246A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
CN103313989B (zh) * 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
US8580399B2 (en) * 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (lt) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP6012611B2 (ja) * 2011-09-28 2016-10-25 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN105189488B (zh) * 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
ES2857848T3 (es) * 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos

Also Published As

Publication number Publication date
HRP20210212T1 (hr) 2021-07-09
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
CN108558871A (zh) 2018-09-21
MX2016007928A (es) 2016-08-03
WO2015100282A1 (en) 2015-07-02
CN106029663B (zh) 2018-06-01
TWI726544B (zh) 2021-05-01
AU2014369982B2 (en) 2019-04-18
HRP20181849T1 (hr) 2018-12-28
RS61479B1 (sr) 2021-03-31
EP3466949A1 (en) 2019-04-10
CY1124061T1 (el) 2022-05-27
UY35916A (es) 2015-06-30
EA201691070A1 (ru) 2016-11-30
RS58014B1 (sr) 2019-02-28
AR099379A1 (es) 2016-07-20
ES2698998T3 (es) 2019-02-06
PH12016500953A1 (en) 2016-06-27
CN106029663A (zh) 2016-10-12
JP6675501B2 (ja) 2020-04-01
HUE041719T2 (hu) 2019-05-28
NZ722326A (en) 2019-09-27
HUE054183T2 (hu) 2021-08-30
PT3087071T (pt) 2018-11-29
SI3087071T1 (sl) 2018-11-30
MA39211B1 (fr) 2019-01-31
CY1121076T1 (el) 2019-12-11
JP6466456B2 (ja) 2019-02-06
PL3466949T3 (pl) 2021-05-31
EP3087071B1 (en) 2018-09-05
AU2014369982A1 (en) 2016-08-04
TW202028203A (zh) 2020-08-01
TWI736517B (zh) 2021-08-21
SMT201800643T1 (it) 2019-01-11
TN2016000238A1 (en) 2017-10-06
PE20160844A1 (es) 2016-09-03
US20160318928A1 (en) 2016-11-03
HRP20210212T8 (hr) 2021-08-20
SMT202100165T1 (it) 2021-05-07
CA2934953C (en) 2022-09-20
KR20160095168A (ko) 2016-08-10
CA2934953A1 (en) 2015-07-02
BR112016013744B1 (pt) 2022-08-30
DK3466949T3 (da) 2021-03-15
EP3087071A1 (en) 2016-11-02
PT3466949T (pt) 2021-02-25
EP3466949B1 (en) 2020-12-23
JP2017505762A (ja) 2017-02-23
BR112016013744A2 (lt) 2017-10-03
ES2857848T3 (es) 2021-09-29
KR102457145B1 (ko) 2022-10-19
IL246359B (en) 2020-04-30
AR123996A2 (es) 2023-02-01
CL2016001629A1 (es) 2017-02-17
IL246359A0 (en) 2016-08-31
PL3087071T3 (pl) 2019-03-29
EA032469B1 (ru) 2019-05-31
TW201609725A (zh) 2016-03-16
SG11201605097SA (en) 2016-07-28
JP2019070014A (ja) 2019-05-09
DK3087071T3 (da) 2019-01-02
MX369491B (es) 2019-11-11
MY176489A (en) 2020-08-12
CN108558871B (zh) 2022-02-18
EA201990240A1 (ru) 2019-06-28
SI3466949T1 (sl) 2021-03-31

Similar Documents

Publication Publication Date Title
LT3466949T (lt) Triciklinis junginys kaip priešvėžinis agentas
LT3060041T (lt) Prostaciklino junginiai
CL2013001994S1 (es) Motocicleta
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
EP2889350A4 (en) ADHESIVE COMPOSITION
DK3022110T3 (da) Cykelsadel
CL2014000309S1 (es) Motocicleta
CL2014000108S1 (es) Motocicleta
DK3027750T3 (da) Biokatalytisk sammensætning
HRP20171890T1 (hr) Supstituirani imidazopiridazini
UA29891S (uk) Мотоцикл
SMT201700115B (it) COMPOSTI BICICLlCI
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
DK2969723T3 (da) Trehjulede cykel
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
DK2947066T3 (da) Phenoxyalkylaminforbindelse
EP2995538A4 (en) MOTORCYCLE
CL2014000196S1 (es) Motocicleta
FR3011527B1 (fr) Guidon repliable
HRP20180722T1 (hr) Spoj benzotiofena
DK2969720T3 (da) Trehjulede cykel
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti
TH1501000971A (th) สารประกอบพิแรโซโลพิริมิดีน
TH1401007838A (th) สารประกอบฟีนอกซิเอธิลไพเพอริดีน
TH1401007117A (th) สารประกอบเตตระไฮโดรไพราโซโลไพริมิดีน